ANI Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nikhil Lalwani
- Full Time Employees
- 897
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 210 Main Street West Baudette MN United States of America 56623
- IPO Date
- May 5, 2000
- CIK
- 0001023024
- Website
- anipharmaceuticals.com
- Similar Companies
- Business
- ANI Pharmaceuticals, Inc. engages in the development, manufacturing, and commercialization of specialty generic pharmaceutical products, proprietary branded products, and rare disease therapies primarily in the United States. Its core products include generic oral solid and liquid dosage forms; specialty and branded pharmaceuticals focused on rare diseases such as Cortrophin Gel for multiple indications, Iluvien and YUTIQ ophthalmic implants; and prescription products in therapeutic areas including ophthalmology, pulmonology, rheumatology, neurology, and nephrology. The company also offers contract development and manufacturing services. Founded in 1971 and headquartered in Baudette, Minnesota, ANI serves healthcare providers, pharmacies, and specialty clinics. In recent years, ANI Pharmaceuticals has focused on expanding its rare disease and ophthalmology segments, marked by its 2024 acquisition of Alimera Sciences, which added the commercial ophthalmic brands Iluvien and YUTIQ, strengthening its presence in the ophthalmology market and boosting pro forma 2024 revenues by approximately $105 million. The acquisition supports an expanded ophthalmology sales team and contributed to robust growth in this therapeutic area. ANI has actively launched multiple generic products, including 14 new products in 2024 such as Promethazine Hydrochloride and Dextromethorphan Hydrobromide oral solution and Ketoconazole Shampoo, driving growth in its generics segment. The company also launched Estradiol Gel, 0.06% in late 2024 and Nitazoxanide Tablets in early 2025, targeting niche limited competition markets. ANI maintains a strong revenue growth trajectory, raising 2025 guidance to $843 million driven by strategic product launches and a strengthened rare disease portfolio. ANI Pharmaceuticals operates primarily in the pharmaceutical industry with segments focusing on generics, specialty pharmaceuticals, and rare diseases, targeting healthcare professionals and patient populations in the U.S. market. It benefits from a diversified product portfolio supported by a robust sales organization specialized in rare and specialty disease areas, backed by recent strategic financing supported by major financial institutions. The company continues to invest in expanding its commercial footprint and product offerings to maintain its leadership in niche pharmaceutical markets and rare therapeutic categories.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals Q1 Earnings Call Highlights
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals (ANIP) is a Top-Ranked Growth Stock: Should You Buy?
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
Why Investors Need to Take Advantage of These 2 Medical Stocks Now